Trial Profile

A Phase 1, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of the LEISH-F2 + MPL-SE Vaccine (Recombinant Three-antigen Leishmania Polyprotein LEISH-F2 With Adjuvant MPL-SE in Combination With Sodium Stibogluconate in the Treatment of Patients With Post Kala-Azar Dermal Leishmaniasis.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 18 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs LEISH-F3 peptide vaccine (Primary) ; Monophosphoryl lipid A (Primary) ; Sodium stibogluconate
Indications Visceral leishmaniasis
Focus Adverse reactions; Pharmacodynamics

27 Jun 2011 Biomarkers information updated
24 Jun 2011 Actual end date (Apr 2011 ) added as reported by ClinicalTrials.gov.
24 Jun 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com